Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026

Phase 3positiveIvonescimabPembrolizumabPositive

AI Analysis

Summary

Akeso announced positive overall survival results from the Phase III HARMONi-2 study comparing ivonescimab versus pembrolizumab in first-line PD-L1-positive NSCLC, presented at WCLC 2026.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Positive overall survival results from HARMONi-2 (AK112-303)

Importance:8/10

Sentiment:

0.80

NSCLCimmunotherapyPD-L1overall survivalPhase 3registrational

Related Companies

$TRAX $WHEN

Read the original article

Published by PR Newswire Biotech on September 13, 2026 6:59 AM

Read Original